Pharmaceutical compositions comprising a RelA enzyme inhibitor and a bactericidal antibiotic, wherein said RelA enzyme inhibitor binds to the RelA enzyme in bacteria to reduce biofilm formation and to degrade biofilms that have been formed. The pharmaceutical compositions can be used to treat bacterial biofilm diseases.

Pharmaceutical compositions comprising a RelA enzyme inhibitor and a bactericidal antibiotic, wherein said RelA enzyme inhibitor binds to the RelA enzyme in bacteria to reduce biofilm formation and to degrade biofilms that have been formed. The pharmaceutical compositions can be used to treat bacterial biofilm diseases.

The invention relates to chiral imidodiphosphates and derivatives thereof having the general formula I, ##STR00001## The compounds are suitable as chiral Brønsted acid catalysts, phase-transfer catalysts, chiral anions for organic salts, metal salts or metal complexes for catalysis.

The invention relates to chiral imidodiphosphates and derivatives thereof having the general formula I, ##STR00001## The compounds are suitable as chiral Brønsted acid catalysts, phase-transfer catalysts, chiral anions for organic salts, metal salts or metal complexes for catalysis.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

A compound of Formula 1

##STR00001## wherein, X represents an alkyl, alkylene, alkenyl, alkenylene, alkynyl or alkynylene group, optionally having at least one substituent selected from the group of —OR.sup.1 and —NR.sup.1R.sup.2, or Y represents —OTBS, —OR.sup.1, —NR.sup.1R.sup.2; Z represents —OR.sup.3 or ═O; and R.sup.1, R.sup.2 and R.sup.3 each independently stand for H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, optionally in the form of enantiomers racemic mixtures, or pharmaceutically acceptable salts thereof, for use as a medicament, in particular for use in anti-viral cancer treatment in mammals and for use in treatment of benign or neoplastic genital Human Papilloma Virus associated diseases and for use in treatment of non-genital warts.

A compound of Formula 1

##STR00001## wherein, X represents an alkyl, alkylene, alkenyl, alkenylene, alkynyl or alkynylene group, optionally having at least one substituent selected from the group of —OR.sup.1 and —NR.sup.1R.sup.2, or Y represents —OTBS, —OR.sup.1, —NR.sup.1R.sup.2; Z represents —OR.sup.3 or ═O; and R.sup.1, R.sup.2 and R.sup.3 each independently stand for H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, optionally in the form of enantiomers racemic mixtures, or pharmaceutically acceptable salts thereof, for use as a medicament, in particular for use in anti-viral cancer treatment in mammals and for use in treatment of benign or neoplastic genital Human Papilloma Virus associated diseases and for use in treatment of non-genital warts.

The present invention relates to novel cyclopropane derivatives represented by Formula I:

##STR00001##

wherein R represents a hydrocarbon group containing 1-20 carbon atoms or an ester containing 1-20 carbon atoms;

wherein R′ represents a C.sub.1-C.sub.6 acyclic carboxylic acid ester, a C.sub.4-C.sub.6 cyclic carboxylic acid ester or —OR″, and R″ is selected from the group consisting of H, a C.sub.1-C.sub.6 acyclic hydrocarbon group, a C.sub.3-C.sub.6 carbocyclic ring and a C.sub.4-C.sub.5 heterocyclic ring; and

wherein the composition is selected from the group consisting of a flavor composition and a fragrance composition.

The present invention relates to novel cyclopropane derivatives represented by Formula I:

##STR00001##

wherein R represents a hydrocarbon group containing 1-20 carbon atoms or an ester containing 1-20 carbon atoms;

wherein R′ represents a C.sub.1-C.sub.6 acyclic carboxylic acid ester, a C.sub.4-C.sub.6 cyclic carboxylic acid ester or —OR″, and R″ is selected from the group consisting of H, a C.sub.1-C.sub.6 acyclic hydrocarbon group, a C.sub.3-C.sub.6 carbocyclic ring and a C.sub.4-C.sub.5 heterocyclic ring; and

wherein the composition is selected from the group consisting of a flavor composition and a fragrance composition.